United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Research Report Information By Service (Pharmaceutical Manufacturing Services, Drug Development Services and Biologics Manufacturing Services), By End User (Small & Mid-Size Pharma, Generic Pharmaceutical Companies, Big Pharma and Other End Users) – United States Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3.Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2.Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, BY SERVICE

6.1. Overview

6.2. Pharmaceutical Manufacturing Services

6.3. Drug Development Services

6.4. Biologics Manufacturing Services

7. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, BY END USER

7.1. Overview

7.2. Small & Mid-Size Pharma

7.3. Generic Pharmaceutical Companies

7.4. Big Pharma

7.5. Other End Users

8. COMPETITIVE LANDSCAPE

8.1. Overview

8.2. Competitive Analysis

8.3. Market Share Analysis

8.4. Major Growth Strategy in the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market,

8.5. Competitive Benchmarking

8.6. Leading Players in Terms of Number of Developments in the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market,

8.7. Key Developments and Growth Strategies

8.7.1. New Product Launch/Service Deployment

8.7.2. Merger &Acquisitions

8.7.3. Joint Ventures

8.8. Major Players Financial Matrix

8.8.1. Sales & Operating Income, 2022

8.8.2. Major Players R&D Expenditure.2022

9. COMPANY PROFILES

9.1. Thermo Fisher Scientific Inc. (US)

9.1.1. Company Overview

9.1.2. Financial Overview

9.1.3. Products Offered

9.1.4. Key Developments

9.1.5. SWOT Analysis

9.1.6. Key Strategies

9.2. Catalent (US)

9.2.1. Company Overview

9.2.2. Financial Overview

9.2.3. Products Offered

9.2.4. Key Developments

9.2.5. SWOT Analysis

9.2.6. Key Strategies

9.3. Lonza Group (Switzerland)

9.3.1. Company Overview

9.3.2. Financial Overview

9.3.3. Products Offered

9.3.4. Key Developments

9.3.5. SWOT Analysis

9.3.6. Key Strategies

9.4. Recipharm AB (Sweden)

9.4.1. Company Overview

9.4.2. Financial Overview

9.4.3. Products Offered

9.4.4. Key Developments

9.4.5. SWOT Analysis

9.4.6. Key Strategies

9.5. Vetter Pharma International GMBH (Germany)

9.5.1. Company Overview

9.5.2. Financial Overview

9.5.3. Products Offered

9.5.4. Key Developments

9.5.5. SWOT Analysis

9.5.6. Key Strategies

9.6. FAMAR Health Care Services (Greece)

9.6.1. Company Overview

9.6.2. Financial Overview

9.6.3. Products Offered

9.6.4. Key Developments

9.6.5. SWOT Analysis

9.6.6. Key Strategies

9.7. AbbVie (US)

9.7.1. Company Overview

9.7.2. Financial Overview

9.7.3. Products Offered

9.7.4. Key Developments

9.7.5. SWOT Analysis

9.7.6. Key Strategies

9.8. Aenova Group (Germany)

9.8.1. Company Overview

9.8.2. Financial Overview

9.8.3. Products Offered

9.8.4. Key Developments

9.8.5. SWOT Analysis

9.8.6. Key Strategies

9.9. Consort Medical (UK))

9.9.1. Company Overview

9.9.2. Financial Overview

9.9.3. Products Offered

9.9.4. Key Developments

9.9.5. SWOT Analysis

9.9.6. Key Strategies

9.10. Almac Group (UK)

9.10.1. Company Overview

9.10.2. Financial Overview

9.10.3. Products Offered

9.10.4. Key Developments

9.10.5. SWOT Analysis

9.10.6. Key Strategies

9.11. Siegfried Holding AG (Switzerland)

9.11.1. Company Overview

9.11.2. Financial Overview

9.11.3. Products Offered

9.11.4. Key Developments

9.11.5. SWOT Analysis

9.11.6. Key Strategies

9.12. Boehringer Ingelheim International GmbH (Germany)

9.12.1. Company Overview

9.12.2. Financial Overview

9.12.3. Products Offered

9.12.4. Key Developments

9.12.5. SWOT Analysis

9.12.6. Key Strategies

9.13. Evonik Industries AG (Germany)

9.13.1. Company Overview

9.13.2. Financial Overview

9.13.3. Products Offered

9.13.4. Key Developments

9.13.5. SWOT Analysis

9.13.6. Key Strategies

10. APPENDIX

10.1. References

10.2. Related Reports

LIST OF TABLES

TABLE 1 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, SYNOPSIS, 2018-2032

TABLE 2 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, ESTIMATES & FORECAST, 2018-2032(USD BILLION)

TABLE 3 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, BY SERVICE, 2018-2032 (USD BILLION)

TABLE 4 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, BY END USER, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET

FIGURE 3 MARKET DYNAMICS FOR THE UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET

FIGURE 4 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, SHARE (%), BY SERVICE, 2022

FIGURE 5 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, SHARE (%), BY END USER, 2022

FIGURE 6 UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 7 THERMO FISHER SCIENTIFIC INC. (US): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 8 THERMO FISHER SCIENTIFIC INC. (US): SWOT ANALYSIS

FIGURE 9 CATALENT (US): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 10 CATALENT (US): SWOT ANALYSIS

FIGURE 11 LONZA GROUP (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 12 LONZA GROUP (SWITZERLAND): SWOT ANALYSIS

FIGURE 13 RECIPHARM AB (SWEDEN): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 14 RECIPHARM AB (SWEDEN): SWOT ANALYSIS

FIGURE 15 VETTER PHARMA INTERNATIONAL GMBH (GERMANY): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 16 VETTER PHARMA INTERNATIONAL GMBH (GERMANY): SWOT ANALYSIS

FIGURE 17 FAMAR HEALTH CARE SERVICES (GREECE): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 FAMAR HEALTH CARE SERVICES (GREECE): SWOT ANALYSIS

FIGURE 19 ABBVIE (US): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 20 ABBVIE (US): SWOT ANALYSIS

FIGURE 21 AENOVA GROUP (GERMANY): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 22 AENOVA GROUP (GERMANY): SWOT ANALYSIS

FIGURE 23 CONSORT MEDICAL (UK): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 CONSORT MEDICAL (UK): SWOT ANALYSIS

FIGURE 25 ALMAC GROUP (UK): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 ALMAC GROUP (UK): SWOT ANALYSIS

FIGURE 27 SIEGFRIED HOLDING AG (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 SIEGFRIED HOLDING AG (SWITZERLAND): SWOT ANALYSIS

FIGURE 29 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY): SWOT ANALYSIS

FIGURE 31 EVONIK INDUSTRIES AG (GERMANY): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 EVONIK INDUSTRIES AG (GERMANY): SWOT ANALYSIS